Abbott Laboratories $ABT Holdings Cut by Brown Miller Wealth Management LLC

Brown Miller Wealth Management LLC cut its position in shares of Abbott Laboratories (NYSE:ABT) by 1.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 42,169 shares of the healthcare product maker’s stock after selling 517 shares during the quarter. Abbott Laboratories makes up 1.8% of Brown Miller Wealth Management LLC’s investment portfolio, making the stock its 6th largest position. Brown Miller Wealth Management LLC’s holdings in Abbott Laboratories were worth $5,735,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC boosted its holdings in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the last quarter. First National Corp MA ADV boosted its stake in Abbott Laboratories by 1.1% in the 1st quarter. First National Corp MA ADV now owns 11,270 shares of the healthcare product maker’s stock worth $1,495,000 after buying an additional 123 shares during the last quarter. Impact Capital Partners LLC grew its holdings in Abbott Laboratories by 3.9% in the 1st quarter. Impact Capital Partners LLC now owns 21,810 shares of the healthcare product maker’s stock valued at $2,893,000 after buying an additional 826 shares during the period. Congress Asset Management Co. increased its stake in shares of Abbott Laboratories by 6.3% during the 1st quarter. Congress Asset Management Co. now owns 3,529 shares of the healthcare product maker’s stock valued at $468,000 after acquiring an additional 210 shares during the last quarter. Finally, Sara Bay Financial lifted its holdings in shares of Abbott Laboratories by 9.2% during the 1st quarter. Sara Bay Financial now owns 8,416 shares of the healthcare product maker’s stock worth $1,101,000 after acquiring an additional 709 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling

In other news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.46% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ABT. BTIG Research lowered their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a report on Friday, July 18th. The Goldman Sachs Group upped their price objective on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday. Royal Bank Of Canada lifted their target price on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Tuesday, July 15th. Mizuho boosted their price target on Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Finally, Leerink Partnrs upgraded Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.39.

Abbott Laboratories Price Performance

Shares of ABT opened at $134.49 on Friday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The firm has a market cap of $234.07 billion, a price-to-earnings ratio of 16.85, a PEG ratio of 2.55 and a beta of 0.69. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The stock has a 50 day moving average of $131.94 and a 200-day moving average of $131.36.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. During the same period last year, the business posted $1.14 earnings per share. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be issued a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.